Humanized Mouse Model for Vaccine Evaluation: an Overview

Overview

Journal Clin Exp Vaccine Res

Date 2024 Feb 16

PMID 38362371

Authors

Shivani Kaushik

Lata Kumari

Rakesh Kumar Deepak

Affiliations

Soon will be listed here.

Abstract

Animal models are essential in medical research for testing drugs and vaccines. These models differ from humans in various respects, so their results are not directly translatable in humans. To address this issue, humanized mice engrafted with functional human cells or tissue can be helpful. We propose using humanized mice that support the engraftment of human hematopoietic stem cells (HSCs) without irradiation to evaluate vaccines that influence patient immunity. For infectious diseases, several types of antigens and adjuvants have been developed and evaluated for vaccination. Peptide vaccines are generally used for their capability to fight cancer and infectious diseases. Evaluation of adjuvants is necessary as they induce inflammation, which is effective for an enhanced immune response but causes adverse effects in some individuals. A trial can be done on humanized mice to check the immunogenicity of a particular adjuvant and peptide combination. Messenger RNA has also emerged as a potential vaccine against viruses. These vaccines need to be tested with human immune cells because they work by producing a particular peptide of the pathogen. Humanized mice with human HSCs that can produce both myeloid and lymphoid cells show a similar immune response that these vaccines will produce in a patient.

Citing Articles

Development of animal models to study aggressive thyroid cancers.

Dutta S, Knauf J Eur Thyroid J. 2025; 14(1).

PMID: 39874138 PMC: 11825169. DOI: 10.1530/ETJ-24-0361.

References

Chianese-Bullock K, Irvin Jr W, Petroni G, Murphy C, Smolkin M, Olson W . A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008; 31(4):420-30. DOI: 10.1097/CJI.0b013e31816dad10. View

Saito Y, Ellegast J, Manz M . Generation of Humanized Mice for Analysis of Human Dendritic Cells. Methods Mol Biol. 2016; 1423:309-20. DOI: 10.1007/978-1-4939-3606-9_22. View

Arunachalam B, Ghosh S, Talwar G, Raghupathy R . A single human monoclonal antibody that confers total protection from tetanus. Hybridoma. 1992; 11(2):165-79. DOI: 10.1089/hyb.1992.11.165. View

Rasmussen M, Fenoy E, Harndahl M, Kristensen A, Kallehauge Nielsen I, Nielsen M . Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity. J Immunol. 2016; 197(4):1517-24. PMC: 4976001. DOI: 10.4049/jimmunol.1600582. View

Gatti R, Meuwissen H, ALLEN H, Hong R, GOOD R . Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968; 2(7583):1366-9. DOI: 10.1016/s0140-6736(68)92673-1. View

Bhatia M, Wang J, Kapp U, Bonnet D, Dick J . Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A. 1997; 94(10):5320-5. PMC: 24676. DOI: 10.1073/pnas.94.10.5320. View

Purcell A, McCluskey J, Rossjohn J . More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007; 6(5):404-14. DOI: 10.1038/nrd2224. View

Bosma G, CUSTER R, Bosma M . A severe combined immunodeficiency mutation in the mouse. Nature. 1983; 301(5900):527-30. DOI: 10.1038/301527a0. View

Mutis T, van Rijn R, Simonetti E, Aarts-Riemens T, Emmelot M, van Bloois L . Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res. 2006; 12(18):5520-5. DOI: 10.1158/1078-0432.CCR-06-0035. View

10.

Shultz L, Brehm M, Garcia-Martinez J, Greiner D . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11):786-98. PMC: 3749872. DOI: 10.1038/nri3311. View

11.

Stoddart C, Maidji E, Galkina S, Kosikova G, Rivera J, Moreno M . Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rγ(-/-) (NSG) BLT mice. Virology. 2011; 417(1):154-60. PMC: 3152643. DOI: 10.1016/j.virol.2011.05.013. View

12.

Torbett B, Picchio G, Mosier D . hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol Rev. 1991; 124:139-64. DOI: 10.1111/j.1600-065x.1991.tb00620.x. View

13.

Villaudy J, Schotte R, Legrand N, Spits H . Critical assessment of human antibody generation in humanized mouse models. J Immunol Methods. 2014; 410:18-27. DOI: 10.1016/j.jim.2014.06.010. View

14.

Ali N, Flutter B, Rodriguez R, Sharif-Paghaleh E, Barber L, Lombardi G . Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype. PLoS One. 2012; 7(8):e44219. PMC: 3429415. DOI: 10.1371/journal.pone.0044219. View

15.

Denton P, Estes J, Sun Z, Othieno F, Wei B, Wege A . Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008; 5(1):e16. PMC: 2194746. DOI: 10.1371/journal.pmed.0050016. View

16.

Abeynaike S, Paust S . Humanized Mice for the Evaluation of Novel HIV-1 Therapies. Front Immunol. 2021; 12:636775. PMC: 8047330. DOI: 10.3389/fimmu.2021.636775. View

17.

Yang J, Rosenberg S . Adoptive T-Cell Therapy for Cancer. Adv Immunol. 2016; 130:279-94. PMC: 6293459. DOI: 10.1016/bs.ai.2015.12.006. View

18.

Garboczi D, Ghosh P, Utz U, Fan Q, Biddison W, Wiley D . Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 1996; 384(6605):134-41. DOI: 10.1038/384134a0. View

19.

McDermott S, Eppert K, Lechman E, Doedens M, Dick J . Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010; 116(2):193-200. DOI: 10.1182/blood-2010-02-271841. View

20.

Bijker M, Melief C, Offringa R, van der Burg S . Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines. 2007; 6(4):591-603. DOI: 10.1586/14760584.6.4.591. View